In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder value. Kezar has retained TD Cowen to support it with the strategic review process. In connection with the evaluation of strategic alternatives, Kezar is in the process of implementing cost-containment and cash conservation measures.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZR:
- Kezar Life Sciences Announces Major Workforce Reduction
- Kezar Life Sciences Repays Loan, Ends Agreement
- Kezar Life Sciences price target lowered to $5 from $7 at Wells Fargo
- Kezar downgraded to Market Perform from Outperform at William Blair
- Kezar Life Sciences Faces Uncertainty with Hold Rating Amid FDA Setback and Strategic Alternatives Exploration